



ANDA 213879

ANDA APPROVAL/TENTATIVE APPROVAL

MSN Pharmaceuticals Inc.
U.S. Agent for MSN Laboratories Private Limited
20 Duke Road
Piscataway, NJ 08854-3714
Attention: Kondal Reddy Bairy
Associate Vice President

Dear Kondal Reddy Bairy:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on September 10, 2019, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Dabigatran Etxilate Capsules, 75 mg, 110 mg, and 150 mg.

Reference is also made to the tentative approval letter issued by this office on March 21, 2022, the complete response letter issued by this office on September 29, 2023, and to any amendments thereafter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act. We have determined your Dabigatran Etxilate Capsules, 75 mg, 110 mg, and 150 mg to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Pradaxa Capsules, 75 mg, 110 mg, and 150 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer).

However, we are unable to grant final approval to your Dabigatran Etxilate Capsules, 110 mg, at this time because of the exclusivity issue noted below. Therefore, your ANDA is **approved** insofar as it pertains to Dabigatran Etxilate Capsules, 75 mg and 150 mg. Your Dabigatran Etxilate Capsules, 110 mg, is **tentatively approved**. This determination is based upon information available to the Agency at this time (e.g., information in your ANDA and the status of current good manufacturing practices (cGMPs) of the facilities used in the manufacturing and testing of the drug product). This determination is subject to change on the basis of new information that may come to our attention.

The reference listed drug (RLD) upon which you have based your ANDA, Boehringer's Pradaxa Capsules, 75 mg, 110 mg, and 150 mg, is subject to periods of patent protection. The following patents and expiration dates (with pediatric exclusivity added)

are currently listed in the Agency's publication titled *Approved Drug Products with Therapeutic Equivalence Evaluations* (the "Orange Book"):

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
7,932,273 (the '273 patent)	March 7, 2026
9,034,822 (the '822 patent)	July 20, 2031
7,866,474 (the '474 patent)	March 2, 2028 (110 mg strength only)

Your ANDA contains paragraph IV certifications to each of the patents under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg, under this ANDA. You have notified the Agency that MSN Laboratories Private Limited (MSN) complied with the requirements of section 505(j)(2)(B) of the FD&C Act, and that no action for infringement was brought against MSN within the statutory 45-day period.

However, we are unable to grant final approval with respect to the 110 mg strength product at this time. Prior to the submission of your ANDA, another applicant or applicants submitted a substantially complete ANDA providing for Dabigatran Etexilate Capsules, 110 mg, and containing a paragraph IV certification. Your ANDA for this strength will be eligible for final approval on August 11, 2024, which is the date that is 180 days after the commercial marketing date identified in section 505(j)(5)(B)(iv) of the FD&C Act.

Upon the foregoing, your ANDA is **approved** insofar as it pertains to the 75 mg and 150 mg product. Your 110 mg product is **tentatively approved**.

I. Approval of Dabigatran Etexilate Capsules, 75 mg and 150 mg

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA referencing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standard for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise

official USP monographs. More information on the USP-NF is available on USP's website at: <https://www.uspnf.com/>.

II. Tentative Approval of Dabigatran Etexilate Capsules, 110 mg

Our decision to tentatively approve your Dabigatran Etexilate Capsules, 110 mg, is based upon information currently available to the agency (i.e., data in your ANDA and the status of current good manufacturing practice (cGMP) of the facilities used in the manufacture and testing of the drug product). This decision is subject to change on the basis of new information that may come to our attention.

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA referencing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

RESUBMISSION

To request final approval, please submit an amendment titled "FINAL APPROVAL REQUESTED" with enough time to permit FDA review prior to the date you believe that your ANDA will be eligible for final approval. A request for final approval that contains no new data, information, or other changes to the ANDA generally requires a period of 3 months for Agency review. Accordingly, such a request for final approval should be submitted no later than 3 months prior to the date on which you seek approval. A request for final approval that contains substantive changes to this ANDA or changes in the status of the manufacturing and testing facilities' compliance with cGMPs will be classified and reviewed according to OGD policy in effect at the time of receipt. Applicants should review available agency guidance for industry related to amendments under the generic drug user fee program to determine the duration of Agency review needed to review the changes submitted. As part of this consideration, applicants should monitor any changes to the RLD that occur after tentative approval, including changes in labeling, patent or exclusivity information, or marketing status. The submission of multiple amendments prior to final approval may also result in a delay in the issuance of the final approval letter.

The amendment requesting final approval should provide the legal/regulatory basis for your request for final approval and should include a copy of a court decision, settlement or licensing agreement, or other information described in 21 CFR 314.107, as appropriate. It should also identify changes, if any, in the conditions under which the ANDA was tentatively approved, i.e., updated information such as final-printed labeling, chemistry, manufacturing, and controls data as appropriate. This amendment should be submitted even if none of these changes were made, and it should be designated clearly in your cover letter as a "MINOR/MAJOR AMENDMENT TO ORIGINAL #2 – FINAL APPROVAL REQUESTED."

In addition to the amendment requested above, the Agency may request, at any time prior to the date of final approval, that you submit an additional amendment containing

information as specified by the Agency. Failure to submit either or, if requested, both types of amendments described above may result in a delay in the issuance of the final approval letter.

This drug product may not be marketed without final Agency approval under section 505(j) of the FD&C Act. The introduction or delivery for introduction into interstate commerce of this drug product before the final approval date is prohibited under section 301 of the FD&C Act. Also, until the Agency issues the final approval letter, this drug product will not be deemed approved for marketing under section 505(j) of the FD&C Act and will not be listed in the Orange Book. Should you believe that there are grounds for issuing the final approval letter prior to August 11, 2024, you should amend your ANDA, accordingly.

REQUIREMENTS AND RECOMMENDATIONS POST APPROVAL

Under applicable statutes, regulations, and guidances, your ANDA may be subject to certain requirements and recommendations post approval, including requirements regarding changes to approved ANDAs, postmarketing reporting, promotional materials, and annual facility fees, among others. For information on post-approval requirements and recommendations for ANDAs and a list of resources for ANDA holders, we refer you to: <https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/requirements-and-resources-approved-andas>.

For further information on the status of this ANDA or upon submitting an amendment to the ANDA, please contact Christopher Jacobs, Regulatory Project Manager, at (240) 402 - 9946.

Sincerely yours,

{See appended electronic signature page}

For Edward M. Sherwood
Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research



John
Ibrahim

Digitally signed by John Ibrahim
Date: 5/22/2024 02:48:34PM
GUID: 542af06d0124375c12e8c1d9fc86e87c